https://www.selleckchem.com/pr....oducts/pf-07220060.h
Patients with chronic cough are typically female and have a mean age of ~ 60years. However, initial pharmacokinetic (PK) characterization of the P2X3-receptor antagonist gefapixant, developed to treat refractory or unexplained chronic cough, was performed in healthy participants who were predominantly younger adult males. The objective of this Phase 1 study was to assess the safety, tolerability, and PK of gefapixant in younger (18-55years) and older (65-80years) males and females. A randomized, double-blind, placebo-controlled stud
Like
Comment
Share
